

NKT cells. Although the precise mechanism remains to be elucidated, such increase of  $\gamma\delta$  T cells in the infected lungs seemed to take place in a different manner from that in NK and NKT cells. Accumulation of NK and NKT cells in lungs after cryptococcal infection was markedly reduced in MCP-1-KO mice, while such reduction was not found in  $\gamma\delta$  T cells. At present, the precise mechanism of  $\gamma\delta$  T cell recruitment remains to be clarified.

Interestingly, clearance of *C. neoformans* in lungs was enhanced in mice receiving a manipulation that deletes  $\gamma\delta$  T cells by administration of specific antibody or targeted disruption of *C $\delta$*  gene. Such increased host defense was associated with the promoted differentiation of Th1 cells and increased production of IFN- $\gamma$ . These observations suggest the down-regulatory role of  $\gamma\delta$  T cells in the host defense to cryptococcal infection. This is in a sharp contrast to the role of NKT cells, which significantly contribute to the development of Th1-type immune response and host resistance to this infection (45). Earlier investigations reported anti-inflammatory  $\gamma\delta$  T cells that produced Th2 cytokines and TGF- $\beta$  (97,98). These observations suggest that these cytokines mediate the down-regulatory effect observed in our study. This speculation was supported by our recent data showing the reduced production of TGF- $\beta$  in the lungs of *C $\delta$* -KO mice totally lacking  $\gamma\delta$  T cells at earlier phase of cryptococcal infection, although the synthesis of Th2 cytokines, IL-4 and IL-10, was not much different from control mice. In this regard, TGF- $\beta$  is known to suppress the host defense to infectious pathogens (99-102). Furthermore, other investigations revealed that  $\gamma\delta$  T cells down-regulate the host defense against infection caused by *L. monocytogenes*, *S. choleraesuis* and *Candida albicans* (92-94). Thus, our study suggests that  $\gamma\delta$  T cells may play down-regulatory roles in the host defense to pulmonary infection with *C. neoformans*.

### 5. Conclusions

Recently, the role of innate immunity in host defense to infectious pathogens has attracted much attention by many




Fig. 1. Regulation of the host defense to cryptococcal infection by NKT and  $\gamma\delta$  T cells.

Host defense to cryptococcal infection is critically regulated by Th1-Th2 cytokine balance. The predominant synthesis of Th1 cytokines over Th2 protects mice from infection, whereas infection is exacerbated under a Th2-dominant condition. NKT cells regulate this balance to promote the host protection, whereas  $\gamma\delta$  T cells counter-regulate this process. Thus, these innate immune lymphocytes may act to keep the host defense in a proper manner, although the mechanism of their activation remains to be elucidated.

investigators according to the biological significance. In our series of studies on cryptococcal infection, the contribution of NKT and  $\gamma\delta$  T cells has been unveiled. Contrast roles of NKT and  $\gamma\delta$  T cells raise a possibility that these innate immune lymphocytes may co-regulate the Th1-mediated response for induction of the moderate host defense, as indicated in Fig. 1.  $\gamma\delta$  T cells may act to keep the balance of Th1-Th2 responses in a proper manner by suppressing the exaggerated Th1 response caused by NKT cells. In pulmonary infection with *C. neoformans*, number of both NKT and  $\gamma\delta$  T cells in the paratracheal lymph nodes increases in parallel with that of DCs (our unpublished data), which could be consistent with the above hypothesis. Interestingly, in toxoplasmal infection,  $\gamma\delta$  T cells appear to play a protective role in the host defense through promoting Th1-mediated immune response, while NKT cells are likely to suppress these responses (91). This is in a sharp contrast to the findings in cryptococcal infection. Thus, NKT and  $\gamma\delta$  T cells are suggested to participate in the regulation of host defense to infection by bridging from innate to antigen-specific acquired immune responses.

### ACKNOWLEDGMENTS

The author is grateful to Drs. Y. Kinjo, K. Uezu, K. Miyagi, T. Kinjo and A. Saito (Division of Infectious Diseases, Department of Internal Medicine, University of the Ryukyus, Okinawa, Japan) for their collaboration in this study.

This work was supported in part by a Grant-in-Aid for Scientific Research (C) (09670292 and 12670261) from the Ministry of Education, Culture, Sport, Science and Technology and by grants from the Ministry of Health, Labour and Welfare, Japan.

### REFERENCES

1. Stevens, D. A. (1990): Fungal infections in AIDS patients. *Br. J. Clin. Pract.*, Suppl. 71, 11-22.
2. Emoto, M., Emoto, M. and Kaufmann, S. H. (2003): Liver NKT cells: an account of heterogeneity. *Trends Immunol.*, 24, 364-369.
3. Horwitz, D. A., Gray, J. D. and Ohtsuka, K. (1999): Role of NK cells and TGF-beta in the regulation of T-cell-dependent antibody production in health and autoimmune disease. *Microbes Infect.*, 1, 1305-1311.
4. Schaible, U. E. and Kaufmann, S. H. (2000): CD1 molecules and CD1-dependent T cells in bacterial infections: a link from innate to acquired immunity? *Semin. Immunol.*, 12, 527-535.
5. Nishimura, T., Kitamura, H., Iwakabe, K., Yahata, T., Ohta, A., Sato, M., Takeda, K., Okumura, K., van Kaer, L., Kawano, T., Taniguchi, M., Nakui, M., Sekimoto, M. and Koda, T. (2000): The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. *Int. Immunol.*, 12, 987-994.
6. Feldmesser, M., Tucker, S. and Casadevall, A. (2001): Intracellular parasitism of macrophages by *Cryptococcus neoformans*. *Trends Microbiol.*, 9, 273-278.
7. Lim, T. S. and Murphy, J. W. (1980): Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from *Cryptococcus neoformans*-sensitized mice. *Infect. Immun.*, 30, 5-11.

8. Mody, C. H., Lipscomb, M. F., Street, N. E. and Toews, G. B. (1990): Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to *Cryptococcus neoformans*. *J. Immunol.*, 144, 1472-1477.
9. Huffnagle, G. B., Yates, J. L. and Lipscomb, M. F. (1991): Immunity to a pulmonary *Cryptococcus neoformans* infection requires both CD4+ and CD8+ T cells. *J. Exp. Med.*, 173, 793-800.
10. Hill, J. O. and Harmsen, A. G. (1991): Intrapulmonary growth and dissemination of an avirulent strain of *Cryptococcus neoformans* in mice depleted of CD4+ or CD8+ T cells. *J. Exp. Med.*, 173, 755-758.
11. Kawakami, K., Tohyama, M., Qifeng, X. and Saito, A. (1997): Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with *Cryptococcus neoformans*: effects of interleukin-12. *Infect. Immun.*, 65, 1307-1312.
12. Koguchi, Y. and Kawakami, K. (2002): Cryptococcal infection and Th1-Th2 cytokine balance. *Int. Rev. Immunol.*, 21, 423-438.
13. Kawakami, K., Tohyama, M., Teruya, K., Kudaken, N., Xie, Q. and Saito, A. (1996): Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with *Cryptococcus neoformans*. *FEMS Immunol. Med. Microbiol.*, 13, 123-130.
14. Huffnagle, G. B., Toews, G. B., Burdick, M. D., Boyd, M. B., McAllister, K. S., McDonald, R. A., Kunkel, S. L. and Strieter, R. M. (1996): Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to *Cryptococcus neoformans*. *J. Immunol.*, 157, 4529-4536.
15. Decken, K., Kohler, G., Palmer-Lehmann, K., Wunderlin, A., Mattner, F., Magram, J., Gately, M. K. and Alber, G. (1998): Interleukin-12 is essential for a protective Th1 response in mice infected with *Cryptococcus neoformans*. *Infect. Immun.*, 66, 4994-5000.
16. Blackstock, R., Buchanan, K. L., Adesina, A. M. and Murphy, J. W. (1999): Differential regulation of immune responses by highly and weakly virulent *Cryptococcus neoformans* isolates. *Infect. Immun.*, 67, 3601-3609.
17. Trinchieri, G. (1995): Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. *Annu. Rev. Immunol.*, 13, 251-276.
18. Robinson, D., Shibuya, K., Mui, A., Zonin, F., Murphy, E., Sana, T., Hartley, S. B., Menon, S., Kastelein, R., Bazan, F. and O'Garra, A. (1997): IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. *Immunity*, 7, 571-581.
19. Kawakami, K., Koguchi, Y., Qureshi, M. H., Miyazato, A., Yara, S., Kinjo, Y., Iwakura, Y., Takeda, K., Akira, S., Kurimoto, M. and Saito, A. (2000): IL-18 contributes to host resistance against infection with *Cryptococcus neoformans* in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells. *J. Immunol.*, 165, 941-947.
20. Taniguchi, M. and Nakayama, T. (2000): Recognition and function of Valpha14 NKT cells. *Semin. Immunol.*, 12, 543-550.
21. Godfrey, D. I., Hammond, K. J. L., Poulton, L. D., Smyth, M. J. and Baxter, A. G. (2000): NKT cells: facts, functions and fallacies. *Immunol. Today*, 21, 573-583.
22. Kronenberg, M. and Gapin, L. (2002): The unconventional lifestyle of NKT cells. *Nat. Rev. Immunol.*, 2, 557-568.
23. Yoshimoto, T., Bendelac, A., Watson, C., Hu-Li, J. and Paul, W. E. (1995): Role of NK1.1+ T cells in a TH2 response and in immunoglobulin E production. *Science*, 270, 1845-1847.
24. Brown, D. R., Fowell, D. J., Corry, D. B., Wynn, T. A., Moskowitz, N. H., Cheever, A. W., Locksley, R. M. and Reiner, S. L. (1996): beta2-microglobulin-dependent NK1.1+T cells are not essential for T helper cell 2 immune responses. *J. Exp. Med.*, 184, 1295-1304.
25. Chen, Y.-H., Chiu, N. M., Mandal, M., Wang, N. and Wang, C. R. (1997): Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. *Immunity*, 6, 459-467.
26. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H. and Taniguchi, M. (1997): CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. *Science*, 278, 1626-1629.
27. Burdin, N., Brossay, L., Koezuka, Y., Smiley, S. T., Grusby, M. J., Taniguchi, M., Hayakawa, K. and Kronenberg, M. (1998): Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates Valpha14 NK T lymphocytes. *J. Immunol.*, 161, 3271-3281.
28. Lehuen, A., Lantz, O., Beaudoin, L., Laloux, V., Carnaud, C., Bendelac, A., Bach, J. F. and Monteiro, R. C. (1998): Overexpression of natural killer T cells protects Valpha14-Jalpha281 transgenic nonobese diabetic mice against diabetes. *J. Exp. Med.*, 188, 1831-1839.
29. Singh, N., Hong, S., Scherer, D. C., Serizawa, I., Burdin, N., Kronenberg, M., Koezuka, Y. and van Kaer, L. (1999): Activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. *J. Immunol.*, 163, 2373-2377.
30. Carnaud, C., Lee, D., Donnars, O., Park, S. H., Beavis, A., Koezuka, Y. and Bendelac, A. (1999): Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. *J. Immunol.*, 163, 4647-4650.
31. Cui, J., Watanabe, N., Kawano, T., Yamashita, M., Kamata, T., Shimizu, C., Kimura, M., Shimizu, E., Oike, J., Koseki, H., Tanaka, Y., Taniguchi, M. and Nakayama, T. (1999): Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Valpha14 natural killer cells. *J. Exp. Med.*, 190, 783-792.
32. Apostolou, I., Takahama, Y., Belmant, C., Kawano, T., Huerre, M., Marchal, G., Cui, J., Taniguchi, M., Nakauchi, H., Fournie, J.-J., Kourilsky, P. and Gachelin, G. (1999): Murine natural killer cells contribute to the granulomatous reaction caused by mycobacterial cell walls. *Proc. Natl. Acad. Sci. USA*, 96, 5141-5146.
33. Gonzalez-Aseguinolaza, G., de Oliveira, C., Tomsaka, M., Hong, S., Bruna-Romero, O., Nakayama, T., Taniguchi, M., Bendelac, A., van Kaer, L., Koezuka, Y. and Tsuji, M. (2000): alpha-galactosylceramide-activated Valpha14 natural killer T cells mediate protection against murine malaria. *Proc. Natl. Acad. Sci. USA*, 97, 8461-8466.
34. Kawakami, K., Kinjo, Y., Uezu, K., Yara, S., Miyagi, K., Koguchi, Y., Nakayama, T., Taniguchi, M. and Saito,

- A. (2002): Minimal contribution of Valpha14 natural killer T cells to Th1 response and host resistance against mycobacterial infection in mice. *Microbiol. Immunol.*, 46, 207-210.
35. Sousa, A. O., Mazzaccaro, R. J., Russell, R. G., Lee, F. K., Turner, O. C., Hong, S., van Kaer, L. and Bloom, B. R. (2000): Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. *Proc. Natl. Acad. Sci. USA*, 97, 4204-4208.
  36. Szalay, G., Zugel, U., Ladel, C. H. and Kaufmann, S. H. E. (1999): Participation of group 2 CD1 molecules in the control of murine tuberculosis. *Microb. Infect.*, 1, 1153-1157.
  37. Ishigami, M., Nishimura, H., Naiki, Y., Yoshioka, K., Kawano, T., Tanaka, Y., Taniguchi, M., Kakumu, S. and Yoshikai, Y. (1999): The roles of intrahepatic Valpha14+ NK1.1+ T cells for liver injury induced by *Salmonella* infection in mice. *Hepatology*, 29, 1799-1808.
  38. Szalay, G., Ladel, C. H., Blum, C., Brossay, L., Kronenberg, M. and Kaufmann, S. H. E. (1999): Anti-CD1 monoclonal antibody treatment reverses the production patterns of TGF-beta2 and Th1 cytokines and ameliorates listeriosis in mice. *J. Immunol.*, 162, 6955-6958.
  39. Nakano, Y., Hisaeda, H., Sakai, T., Zhang, M., Maekawa, Y., Zhang, T. and Himeno, K. (2001): Role of innate immune cells in protection against *Toxoplasma gondii* at inflamed site. *J. Med. Invest.*, 48, 73-80.
  40. Kawakami, K., Yamamoto, N., Kinjo, Y., Miyagi, K., Nakasone, C., Uezu, K., Kinjo, T., Nakayama, T., Taniguchi, M. and Saito, A. (2003): Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against *Streptococcus pneumoniae* infection. *Eur. J. Immunol.*, 33, 3322-3330.
  41. Ishikawa, H., Hisaeda, H., Taniguchi, M., Nakayama, T., Sakai, T., Maekawa, Y., Nakano, Y., Zhang, M., Zhang, T., Nishitani, M., Takashima, M. and Himeno, K. (2000): CD4+ Valpha14 NKT cells play a crucial role in an early stage of protective immunity against infection with *Leishmania major*. *Int. Immunol.*, 12, 1267-1274.
  42. Duthie, M. S., Wleklinski-Lee, M., Smith, S., Nakayama, T., Taniguchi, M. and Kahn, S. J. (2002): During *Trypanosoma cruzi* infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycoposphoinositol-modified surface protein. *Infect. Immun.*, 70, 36-48.
  43. Nieuwenhuis, E. E., Matsumoto, T., Exley, M., Schleipman, R. A., Glickman, J., Bailey, D. T., Corazza, N., Colgan, S. P., Onderdonk, A. B. and Blumberg, R. S. (2002): CD1d-dependent macrophage-mediated clearance of *Pseudomonas aeruginosa* from lung. *Nat. Med.*, 8, 588-593.
  44. Kumar, H., Belperron, A., Barthold, S. W. and Bockenstedt, L. K. (2000): CD1d deficiency impairs murine host defense against the spirochete, *Borrelia burgdorferi*. *J. Immunol.*, 165, 4797-4801.
  45. Mannoer, M. K., Weerasinthe, A., Halder, R. C., Reza, S., Morshed, M., Ariyasinghe, A., Watanabe, H., Sekikawa, H. and Abo, T. (2001): Resistance to malarial infection is achieved by the cooperation of NK1.1+ and NK1.1- subsets of intermediate TCR cells which are constituents of innate immunity. *Cell. Immunol.*, 211, 96-104.
  46. Kawakami, K., Kinjo, Y., Uezu, K., Yara, S., Miyagi, K., Koguchi, Y., Nakayama, T., Taniguchi, M. and Saito, A. (2001): Monocyte chemoattractant protein-1-dependent increase of Valpha 14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. *J. Immunol.*, 167, 6525-6532.
  47. Rossi, D. and Zlotnik, A. (2000): The biology of chemokines and their receptors. *Annu. Rev. Immunol.*, 217, 217-242.
  48. Maghazachi, A. A., Skalhegg, B. S., Rolstad, B. and Al-Aoukaty, A. (1997): Interferon-inducible protei-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins. *FASEB J.*, 11, 765-774.
  49. Taub, D. D., Sayers, T. J., Carter, C. R. and Ortaldo, J. R. (1995): Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytotoxicity. *J. Immunol.*, 155, 3877-3888.
  50. Allavena, P., Bianchi, G., Zhou, D., van Damme, J., Jilek, P., Sozzani, S. and Mantovani, A. (1994): Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. *Eur. J. Immunol.*, 24, 3233-3236.
  51. Maghazachi, A. A., Al-Aoukaty, A. and Schall, T. J. (1994): C-C chemokine induce the chemotaxis of NK and IL-2-activated NK cells. Role for G-proteins. *J. Immunol.*, 153, 4969-4977.
  52. Loetscher, P., Seitz, M., Clark-Lewis, I., Baggiolini, M. and Moser, B. (1996): Activation of NK cells by CC chemokines. Chemotaxis, Ca<sup>2+</sup> mobilization, and enzyme release. *J. Immunol.*, 156, 322-327.
  53. Giancarlo, B., Silvano, S., Albert, Z., Mantovani, A. and Allavena, P. (1996): Migratory response of human natural killer cells to lymphotactin. *Eur. J. Immunol.*, 26, 3238-3241.
  54. Faunce, D. E., Sonoda, K. and Stein-Streilein, J. (2001): MIP-2 recruits NKT cells to the spleen during tolerance induction. *J. Immunol.*, 166, 313-321.
  55. Joyce, S., Woods, A. S., Yewdell, J. W., Bennink, J. R., de Silva, A. D., Boesteanu, A., Balk, S. P., Cotter, R. J. and Brutkiewicz, R. R. (1998): Natural ligand of mouse CD1d: cellular glycosylphosphatidyl-inositol. *Science*, 279, 1541-1544.
  56. Schofield, L., McConville, M. J., Hansen, D., Campbell, A. S., Fraser-Reid, B., Grusby, M. J. and Tachado, S. D. (1999): CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. *Science*, 283, 225-229.
  57. Molano, A., Park, S. H., Chiu, Y. H., Nossair, S., Bendelac, A. and Tsuji, M. (2000): Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and anti-malarial responses. *J. Immunol.*, 164, 5005-5009.
  58. Procopio, D. O., Almeida, I. C., Torrecilhas, A. C., Cardoso, J. E., Teyton, L., Travassos, L. R., Bendelac, A. and Gazzinelli, R. T. (2002): Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from *Trypanosoma cruzi* bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. *J. Immunol.*, 169, 3926-3933.
  59. Brigl, M., Bry, L., Kent, S. C., Gumperz, J. E. and

- Brenner, M. B. (2003): Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. *Nat. Immunol.*, 4, 1230-1237.
60. Toura, I., Kawano, T., Akutsu, Y., Nakayama, T., Ochiai, T. and Taniguchi, M. (1999): Inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. *J. Immunol.*, 163, 2387-2391.
  61. Gonzalez-Aseguinolaza, G., Van Kaer, L., Bergmann, C. C., Wilson, J. M., Schmieg, J., Kronenberg, M., Nakayama, T., Taniguchi, M., Koezuka, Y. and Tsuji, M. (2002): Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. *J. Exp. Med.*, 195, 617-624.
  62. Kawakami, K., Kinjo, Y., Yara, S., Koguchi, Y., Uezu, K., Nakayama, T., Taniguchi, M. and Saito, A. (2001): Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with *Cryptococcus neoformans*. *Infect. Immun.*, 69, 213-220.
  63. Kawakami, K., Kinjo, Y., Yara, S., Uezu, K., Koguchi, Y., Tohyama, M., Azuma, M., Takeda, K., Akira, S. and Saito, A. (2001): Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis. *Infect. Immun.*, 69, 6643-6650.
  64. Chackerian, A., Alt, J., Perera, V. and Behar, S. M. (2002): Activation of NKT cells protects mice from tuberculosis. *Infect. Immun.*, 70, 6302-6309.
  65. Hayday, A. C. (2000): Gamma/delta cells: a right time and a right place for a conserved third way of protection. *Annu. Rev. Immunol.*, 18, 975-1026.
  66. Lahn, M. (2000): The role of gamma/delta T cells in the airways. *J. Mol. Med.*, 78, 409-425.
  67. Augustin, A., Kubo, R. T. and Sim, G. K. (1989): Resident pulmonary lymphocytes expressing the gamma/delta T-cell receptor. *Nature*, 340, 239-241.
  68. Hayes, S. M., Sirt, A., Jacob, S., Sim, G. K. and Augustin, A. (1996): Role of IL-7 in the shaping of the pulmonary gamma delta T cell repertoire. *J. Immunol.*, 156, 2723-2729.
  69. Sim, G. K., Rajaserkar, R., Dessing, M. and Augustin, A. (1994): Homing and in situ differentiation of resident pulmonary lymphocytes. *Int. Immunol.*, 6, 1287-1295.
  70. Tanaka, Y., Morita, C. T., Tanaka, Y., Nieves, E., Brenner, M. B. and Bloom, B. R. (1995): Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. *Nature*, 375, 155-158.
  71. Bukowski, J. F., Morita, C. T. and Brenner, M. B. (1999): Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. *Immunity*, 11, 57-65.
  72. Holoshitz, J., Vila, L. M., Keroack, B. J., McKinley, D. R. and Bayne, N. K. (1992): Dual antigenic recognition by cloned human gamma delta T cells. *J. Clin. Invest.*, 89, 308-314.
  73. O'Brien, R. L., Happ, M. P., Dallas, A., Palmer, E., Kubo, R. and Born, W. K. (1989): Stimulation of a major subset of lymphocytes expressing T cell receptor gamma delta by an antigen derived from *Mycobacterium tuberculosis*. *Cell*, 57, 667-674.
  74. Born, W., Hall, L., Dallas, A., Boymel, J., Shinnick, T., Young, D., Brennan, P. and O'Brien, R. (1990): Recognition of a peptide antigen by heat shock-reactive gamma delta T lymphocytes. *Science*, 249, 67-69.
  75. O'Brien, R. L., Fu, Y. X., Cranfill, R., Dallas, A., Ellis, C., Reardon, C., Lang, J., Carding, S. R., Kubo, R. and Born, W. (1992): Heat shock protein Hsp60-reactive gamma delta cells: a large, diversified T-lymphocyte subset with highly focused specificity. *Proc. Natl. Acad. Sci. USA*, 89, 4348-4352.
  76. Janeway, C. A. Jr., Jones, B. and Hayday, A. (1988): Specificity and function of T cells bearing gamma delta receptors. *Immunol. Today*, 9, 73-76.
  77. Porcelli, S., Brenner, M. B. and Band, H. (1991): Biology of the human gamma delta T-cell receptor. *Immunol. Rev.*, 120, 137-183.
  78. Morita, C. T., Verma, S., Aparicio, P., Martinez, C., Spits, H. and Brenner, M. B. (1991): Functionally distinct subsets of human gamma/delta T cells. *Eur. J. Immunol.*, 21, 2999-3007.
  79. Eichelberger, M., Allan, W., Carding, S. R., Bottomly, K. and Doherty, P. C. (1991): Activation status of the CD4<sup>+</sup>8<sup>-</sup> gamma delta-T cells recovered from mice with influenza pneumonia. *J. Immunol.*, 147, 2069-2074.
  80. Taguchi, T., Aicher, W. K., Fujihashi, K., Yamamoto, M., McGhee, J. R., Bluestone, J. A. and Kiyono, H. (1991): Novel function for intestinal intraepithelial lymphocytes. Murine CD3<sup>+</sup>, gamma/delta TCR<sup>+</sup> T cells produce IFN-gamma and IL-5. *J. Immunol.*, 147, 3736-3744.
  81. Bluestone, J. A., Cron, R. Q., Barrett, T. A., Houlden, B., Sperling, A. I., Dent, A., Hedrick, S., Rellahan, B. and Matis, L. A. (1991): Repertoire development and ligand specificity of murine TCR gamma delta cells. *Immunol. Rev.*, 120, 5-33.
  82. Ferrick, D. A., Schrenzel, M. D., Mulvania, T., Hsieh, B., Ferlin, W. G. and Lepper, H. (1995): Differential production of interferon-gamma and interleukin-4 in response to Th1- and Th2-stimulating pathogens by gamma delta T cells in vivo. *Nature*, 373, 255-257.
  83. Roessner, K., Wolfe, J., Shi, C., Sigal, L. H., Huber, S. and Budd, R. C. (2003): High expression of Fas ligand by synovial fluid-derived gamma delta T cells in Lyme arthritis. *J. Immunol.*, 170, 2702-2710.
  84. Moore, T. A., Moore, B. B., Newstead, M. W. and Standiford, T. J. (2000): Gamma delta-T cells are critical for survival and early proinflammatory cytokine gene expression during murine *Klebsiella pneumoniae*. *J. Immunol.*, 165, 2643-2650.
  85. Takano, M., Nishimura, H., Kimura, Y., Mokuno, Y., Washizu, J., Itohara, S., Nimura, Y. and Yoshikai, Y. (1998): Protective roles of gamma delta T cells and interleukin-15 in *Escherichia coli* infection in mice. *Infect. Immun.*, 66, 3270-3278.
  86. Hiromatsu, K., Yoshikai, Y., Matsuzaki, G., Ohga, S., Muramori, K., Matsumoto, K., Bluestone, J. A. and Nomoto, K. (1992): A protective role of gamma/delta T cells in primary infection with *Listeria monocytogenes* in mice. *J. Exp. Med.*, 175, 49-56.
  87. Ladel, C. H., Blum, C., Dreher, A., Reifenberg, K. and Kaufmann, S. H. (1995): Protective role of gamma/delta T cells and alpha/beta T cells in tuberculosis. *Eur. J. Immunol.*, 25, 2877-2881.
  88. King, D. P., Hyde, D. M., Jackson, K. A., Novosad, D. M., Ellis, T. N., Putney, L., Stovall, M. Y., van Winkle, L. S., Beaman, B. L. and Ferrick, D. A. (1999): Cutting

- edge: protective response to pulmonary injury requires gamma delta T lymphocytes. *J. Immunol.*, 162, 5033-5036.
89. Jones-Carson, J., Vazquez-Torres, A., van der Heyde, H. C., Warner, T., Wagner, R. D. and Balish, E. (1995): Gamma delta T cell-induced nitric oxide production enhances resistance to mucosal candidiasis. *Nat. Med.*, 1, 552-557.
  90. Rosat, J. P., MacDonald, H. R. and Louis, J. A. (1993): A role for gamma delta + T cells during experimental infection of mice with *Leishmania major*. *J. Immunol.*, 150, 550-555.
  91. Hisaeda, H., Nagasawa, H., Maeda, K., Maekawa, Y., Ishikawa, H., Ito, Y., Good, R. A. and Himeno, K. (1995): Gamma delta T cells play an important role in hsp65 expression and in acquiring protective immune responses against infection with *Toxoplasma gondii*. *J. Immunol.*, 155, 244-251.
  92. O'Brien, R. L., Yin, X., Huber, S. A., Ikuta, K. and Born, W. K. (2000): Depletion of a gamma delta T cell subset can increase host resistance to a bacterial infection. *J. Immunol.*, 165, 6472-6479.
  93. Emoto, M., Nishimura, H., Sakai, T., Hiromatsu, K., Gomi, H., Itoharu, S. and Yoshikai, Y. (1995): Mice deficient in gamma delta T cells are resistant to lethal infection with *Salmonella choleraesuis*. *Infect. Immun.*, 63, 3736-3738.
  94. Wormley, F. L. Jr., Steele, C., Wozniak, K., Fujihashi, K., McGhee, J. R. and Fidel, P. L. Jr. (2001): Resistance of T-cell receptor delta-chain-deficient mice to experimental *Candida albicans* vaginitis. *Infect. Immun.*, 69, 7162-7164.
  95. Williams, D. M., Grubbs, B. G., Kelly, K., Pack, E. and Rank, R. G. (1996): Role of gamma-delta T cells in murine *Chlamydia trachomatis* infection. *Infect. Immun.*, 64, 3916-3919.
  96. Uezu, K., Kawakami, K., Miyagi, K., Kinjo, Y., Kinjo, T., Ishikawa, H. and Saito, A. (2004): Accumulation of gammadelta T cells in the lungs and their regulatory roles in Th1 response and host defense against pulmonary infection with *Cryptococcus neoformans*. *J. Immunol.*, 172, 7629-7634.
  97. Wesch, D., Glatzel, A. and Kabelitz, D. (2001): Differentiation of resting human peripheral blood gamma delta T cells toward Th1- or Th2-phenotype. *Cell. Immunol.*, 212, 110-117.
  98. Nagaeva, O., Jonsson, L. and Mincheva-Nilsson, L. (2002): Dominant IL-10 and TGF-beta mRNA expression in gamma delta T cells of human early pregnancy decidua suggests immunoregulatory potential. *Am. J. Reprod. Immunol.*, 48, 9-17.
  99. Reed, S. G. (1999): TGF-beta in infections and infectious diseases. *Microbes Infect.*, 1, 1313-1325.
  100. Letterio, J. J. and Roberts, A. B. (1998): Regulation of immune responses by TGF-beta. *Annu. Rev. Immunol.*, 16, 137-161.
  101. Hirsch, C. S., Ellner, J. J., Blinkhorn, R. and Toossi, Z. (1997): In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against *Mycobacterium tuberculosis* by natural inhibitors of transforming growth factor beta. *Proc. Natl. Acad. Sci. USA*, 94, 3926-3931.
  102. Li, J., Hunter, C. A. and Farrell, J. P. (1999): Anti-TGF-beta treatment promotes rapid healing of *Leishmania major* infection in mice by enhancing in vivo nitric oxide production. *J. Immunol.*, 162, 974-979.

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Zheng H.-Y., Kitamura T., Takasaka T., Chen Q., and Yogo Y.	Unambiguous identification of JC polyomavirus strains transmitted from parents to children.	Arch. Virol.	149	261-273	2004
Zheng H.-Y., Yasuda Y., Kato S., Kitamura T., and Yogo Y.	Stability of JC virus-coding sequences in a case of progressive multifocal leukoencephalopathy where the viral control region was rearranged markedly.	Arch. Pathol. Lab. Med.	128	275-278	2004
Zheng H.-Y., Zhao P., Suganami H., Ohasi Y., Ikegaya H., Kim J.C., Sugimoto C., Takasaka T., Kitamura T., and Yogo Y.:	Regional distribution of two related Northeast Asian genotypes of JC virus, CY-a and -b: implications for the dispersal of Northeast Asians.	Microbes Infect.	6	596-603	2004
Yogo Y., Sugimoto C., Zheng H.-Y., Ikegaya H., Takasaka T., and Kitamura T.	JC virus genotyping offers a new paradigm in the study of human populations.	Rev. Med. Virol.	14	179-191	2004
Kato A., Kitamura T., Takasaka T., Zheng H.-Y., Tominaga T., and Yogo Y.	Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsillar hypertrophy.	J. Neurovirol.	10	244-249	2004
Takasaka T., Goya N., Tokumoto T., Tanabe K., Toma H., Ogawa Y., Hokama S., Momose A., Funyu T., Fujioka T., Omori S., Akiyama H., Chen Q., Zheng H.-Y., Ohta N., Kitamura T., and Yogo Y.	Subtypes of BK virus prevalent in Japan and variation in their transcriptional control region.	J. Gen. Virol.	85	2821-2827	2004
Takasaka A., Miranda J.J., Sugimoto C., Paraguison R., Zheng H.-Y., Kitamura T., and Yogo Y.	Genotypes of JC Virus in Southeast Asia and the Western Pacific: Implications for Human Migrations from Asia to the Pacific.	Anthropol. Sci.	112	53-59	2004
Miranda J.J., Takasaka T., Zheng H.-Y., Kitamura T., and Yogo Y.	JC virus genotype profile in the Mamanwa, a Philippine Negrito tribe, and implications for its population history.	Anthropol. Sci.	112	173-178	2004
Ikegaya H., Zheng H.-Y., Saukko P.J., Varesmaa-Korhonen L., Hovi T., Vesikari T., Suganami H., Takasaka T., Sugimoto C., Ohasi Y., Kitamura T., and Yogo Y.	Genetic diversity of JC virus in the Saami and the Finns: Implications for their population history.	Am. J. Phys. Anthropol.			2005 (in press)
Takasaka T., Kitamura T., Sugimoto C., Guo J., Zheng H.-Y., and Yogo Y.	Phylogenetic analysis of the major African genotype (Af2) of JC virus: Implications for the origin and dispersals of modern Africans.	Am. J. Phys. Anthropol.			2005 (in press)
Zheng H.-Y., Ikegaya H., Nakajima M., Sakurada K., Takasaka T., Kitamura T., and Yogo Y.	Two distinct genotypes (MY-x and MX) of JC virus previously identified in Hokkaido Ainu.	Anthropol. Sci.			2005 (in press)
Ikegaya H., Iwase H., Zheng H.-Y., Nakajima M., Sakurada K., Takatori T., Fukayama M., Kitamura T., and Yogo Y.	JC virus genotyping using formalin-fixed, paraffin-embedded renal tissues.	J. Virol. Methods			2005 (in press)

## **Unambiguous identification of *JC polyomavirus* strains transmitted from parents to children**

**H.-Y. Zheng, T. Kitamura, T. Takasaka, Q. Chen, and Y. Yogo**

Department of Urology, Faculty of Medicine, The University of Tokyo,  
Tokyo, Japan

Received May 9, 2003; accepted August 20, 2003  
Published online October 30, 2003 © Springer-Verlag 2003

**Summary.** *JC polyomavirus* (JCV), the etiological agent of progressive multifocal leukoencephalopathy, is ubiquitous in humans, infecting children asymptotically, then persisting in renal tissue. It has been proposed that JCV is transmitted mainly from parents to children through long-term cohabitation. The objective of this study was to further elucidate the mode of JCV transmission. In 5 families, we selected parent/child pairs between whom JCV was probably transmitted (judged on the basis of the identity of a 610-bp JCV DNA sequence between the parent and child). We established 5 to 9 complete JCV DNA clones from the urine of each parent or child. The complete sequences of these clones were determined and compared in each family. Nucleotide substitutions were detected in 4 parents and 1 child, and sequence rearrangements (deletions or duplications) were found in 2 parents and 2 children. Phylogenetic comparison of the detected sequences indicated that the diversity of JCV DNA sequences was generated in each family (i.e. not caused by multiple infection). We found that in 4 of the 5 families, a sequence detected in the parent was completely identical to one in the child. These findings provided further support for the proposed mode of JCV transmission, i.e. parent-to-child transmission during cohabitation.

### **Introduction**

*JC polyomavirus* (JCV) is the causative agent of a fatal demyelinating disease in the central nervous system, known as progressive multifocal leukoencephalopathy (PML) [26, 29]. However, this virus is ubiquitous in the human population. Primary infection usually occurs asymptotically during childhood [30, 40]. JCV persists in the kidney of most adults, who excrete progeny viruses in urine [1, 9, 20, 22, 39]. JCV may also persist in other sites, including peripheral blood lymphocytes, lymphoid tissues, and the central nervous system [11].

Serological studies [10, 30, 37, 40] have shown that children are infected with JCV after birth (i.e. JCV transmission is categorized as horizontal [28]). Using urinary JCV DNA, several attempts have been made to further elucidate the mode of JCV transmission. (i) Kunitake et al. [24] PCR-amplified a 610-bp JCV DNA region (IG region) from urine specimens collected from all members of 7 families. (The IG region was previously established as a region of the JCV DNA that contains relatively abundant sites for typing JCV DNAs [7].) JCV strains were identified by the nucleotide sequences of the amplified IG regions. Strains detected in half of the JCV-positive children were identified in their parents. Furthermore, Kunitake et al. [24] detected the same IG sequences in the offspring as well as in the fathers (3 cases) or mothers (3 cases) of the 6 families, suggesting that JCV transmission occurs both maternally and paternally. (ii) Kato et al. [17] studied whether JCV have been transmitted from the American population to the Japanese population both existing on a small island, Okinawa, Japan. No American JCV genotypes were detected in the Japanese population. (iii) Suzuki et al. [36] collected urine samples in Los Angeles from second and third generation Japanese-Americans whose parents and grandparents were all Japanese. From these urine samples, 2 genotypes (CY and MY) of JCV that predominantly occur in homeland Japanese [23] were mainly detected in each generation of the Japanese-Americans. Taken these findings together, it is likely that JCV is transmitted mainly from parents to children during long-term cohabitation.

In this study, we attempted to gain further insights into the transmission of JCV. We selected 5 families in each of which JCV was probably transmitted from a parent to a child (2 children in a single family). This judgment was made on the basis of the identity of the 610-bp IG sequence between the parent and child. At least 5 complete JCV DNA clones were established and sequenced from the urine of each parent or child. Although JCV DNA sequences significantly varied in most families, we detected a completely identical JCV DNA sequence in both the parent and the child belonging to each of 4 families. These findings provided support for the proposed mode of JCV transmission, i.e. parent-to-child transmission during cohabitation.

## Materials and methods

### *Subjects*

Five families were studied (Table 1). Families A to C were previously studied by Kunitake et al. [24] (families A, B, and C corresponded to families 3, 2, and 5, respectively, studied by Kunitake et al. [24]). Families D and E were first investigated in this study. A parent/child pair (2 children in family A) was selected in each family on the basis of the identity of the 610-bp IG sequence detected in their urine. All subjects were immunocompetent.

### *DNA analysis*

Entire JCV DNAs were cloned into pUC19 at the unique *Bam*HI site as described previously [42]. The resultant complete JCV DNA clones were prepared using a QIAGEN Plasmid Midi



**Table 1.** Parents and children included in this study<sup>a</sup>

Family	Member	Age (yr)	No. of clones analyzed
A	Parent (father) <sup>b</sup>	52	6
A	Child 1 (daughter)	29	5
A	Child 2 (daughter)	26	5
B	Parent (mother) <sup>c</sup>	84	6
B	Child (daughter)	59	6
C	Parent (father) <sup>b</sup>	86	9
C	Child (son)	60	5
D	Parent (mother) <sup>d</sup>	56	5
D	Child (son)	26	5
E	Parent (mother) <sup>d</sup>	62	5
E.	Child (son)	25	5

<sup>a</sup>A parent/child pair (2 children in family A) was selected in each family on the basis of the identity of the 610-bp IG sequence detected in their urine

<sup>b</sup>JCV DNA was not detected in the mother

<sup>c</sup>No information on the JCV DNA sequence in the father was available because of his death

<sup>d</sup>The 610-bp IG sequence in the father significantly diverged from that in the child

kit (QIAGEN GmbH, Hilden, Germany). Purified plasmids were sequenced as described previously [35].

#### *Phylogenetic analysis*

The noncoding regulatory region of the JCV genome was excluded from phylogenetic analysis, as this region is hypervariable especially in JCV isolates derived from the brains of PML patients [16, 41, 43]. The determined and reference sequences were aligned using the CLUSTAL W program [38]. The aligned sequences were subjected to phylogenetic analysis using the neighbor-joining (NJ) method [32]. Phylogenetic trees were constructed using CLUSTAL W, and divergences were estimated by the 2-parameter method [19]. Phylogenetic trees were visualized using TREEVIEW [31]. To assess the confidence of branching patterns of the NJ trees, 1,000 bootstrap replications were performed [12]. Bootstrap probabilities larger than 70% were considered to be significant [15].

## **Results**

### *Sequences detected in each family*

We attempted to establish complete JCV DNA clones from urine samples collected from parents and children belonging to families A to E. We obtained 5 to 9 complete JCV DNA clones from each subject (Table 1). We sequenced all of these clones and deposited the obtained sequences in GSDB, EMBL, DDBJ, and NCBI nucleotide sequence databases with the accession numbers indicated in Table 2.

Two sequences, FA-1 and FA-1a, were detected in family A (Table 3). In reference to FA-1, FA-1a carried a 63-bp deletion within the VP2/3 gene spanning

**Table 2.** Complete JCV DNA sequences determined in this study

Family	Sequence	Genotype	Accession no. <sup>a</sup>
A	FA-1	B1-b	AB103387
A	FA-1a	B1-b	AB103402
B	FB-1	MY-b	AB103403
B	FB-2	MY-b	AB103404
B	FB-3	MY-b	AB103405
C	FC-1	CY	AB103406
C	FC-1a	CY	AB103407
C	FC-2	CY	AB103408
C	FC-3	CY	AB103409
C	FC-3a	CY	AB104487
C	FC-4	CY	AB103410
C	FC-4a	CY	AB103411
C	FC-5	CY	AB103412
D	FD-1	MY-b	AB103413
D	FD-1a	MY-b	AB103414
D	FD-2	MY-b	AB103415
D	FD-3	MY-b	AB103416
E	FE-1	CY	AB103417
E	FE-2	CY	AB103418
E	FE-3	CY	AB103419
- <sup>b</sup>	HA <sup>c</sup>	MY-b	AB103420
-	HS <sup>c</sup>	MY-b	AB103421
-	KF <sup>c</sup>	MY-b	AB103422
-	ST <sup>c</sup>	MY-b	AB103423

<sup>a</sup>GSDB, EMBL, DDBJ, and NCBI nucleotide sequence databases<sup>b</sup>Unrelated to families A–E<sup>c</sup>Clones previously established [40]**Table 3.** Comparison and distribution of complete JCV DNA sequences detected in family A

Sequence	Rearrangement	No. of clones with the indicated sequence in:		
		Parent	Child 1	Child 2
FA-1	- <sup>a</sup>	6	5	4
FA-1a	del <sup>b</sup>	0	0	1

<sup>a</sup>None<sup>b</sup>Deletion of a 63-bp sequence (nt 1281–1343) within the VP2/3 gene

from nucleotide (nt) 1281 to 1343 (nucleotide numbers are those of an archetype isolate, CY [18], starting from the midpoint of the origin of replication and proceeding clockwise). All clones from the parent and child 1 and most clones from child 2 contained FA-1, while a single clone from child 2 had FA-1a.

**Table 4.** Comparison and distribution of complete JCV DNA sequences detected in family B

Sequence	Nucleotide substitution at:		Rearrangement	No. of clones with the indicated sequence in:	
	nt 1667	nt 4109		Parent	Child
FB-1	A	A	— <sup>a</sup>	3	0
FB-2	G	A	—	2	6
FB-3	G	G	—	1	0

<sup>a</sup>None**Table 5.** Comparison and distribution of complete JCV DNA sequences detected in family C

Sequence	Nucleotide substitution at:				Rearrangement	No. of clones with the indicated sequence in:	
	nt 2612	nt 3065	nt 3202	nt 3310		Parent	Child
FC-1	G	G	A	A	— <sup>a</sup>	0	4
FC-1a	G	G	A	A	del <sup>b</sup>	0	1
FC-2	G	G	A	T	—	1	0
FC-3	G	A	A	A	—	2	0
FC-3a	G	A	A	A	dup <sup>c</sup>	1	0
FC-4	G	G	C	A	—	3	0
FC-4a	G	G	C	A	dup <sup>d</sup>	1	0
FC-5	T	G	A	G	—	1	0

<sup>a</sup>None<sup>b</sup>Deletion of a 38-bp segment (nt 4931–4968) within the LT exon<sup>c</sup>Duplication of a 36-bp segment (nt 204–239) within the regulatory region<sup>d</sup>Duplication of a 52-bp segment (nt 212–263) within the regulatory region

Three sequences, FB-1 to -3, were detected in family B (Table 4). These sequences were distinguishable by nucleotide substitutions at 2 sites, nt 1667 and 4109, within the VP1 and large T antigen (abbreviated as LT) genes, respectively. FB-1 to -3 were found in the parent, but only FB-2 was found in the child.

Eight sequences, FC-1, -1a, -2, -3, -3a, -4, -4a, and -5, were detected in family C (Table 5). These sequences were distinguishable by substitutions at 4 sites, nt 2612, 3065, 3202, and 3310, all locating within the LT gene, and by a 38-bp deletion within the LT gene, and 36-bp and 52-bp duplications within the regulatory region. Six sequences (FC-2, -3, -3a, -4, -4a, and -5) were found in the parent, and 2 sequences (FC-1 and FC-1a) were found in the child.

Four sequences, FD-1, -1a, -2, and -3, were detected in family D (Table 6). These sequences were distinguishable by nucleotide substitutions at 2 sites, nt 2933 and 3308, within the LT gene and by a 28-bp deletion within the regulatory

**Table 6.** Comparison and distribution of complete JCV DNA sequences detected in family D

Sequence	Nucleotide substitution at:		Rearrangement	No. of clones with the indicated sequence in:	
	nt 2933	nt 3308		Parent	Child
FD-1	C	A	— <sup>a</sup>	2	5
FD-1a	C	A	del <sup>b</sup>	1	0
FD-2	C	T	—	1	0
FD-3	T	A	—	1	0

<sup>a</sup>None<sup>b</sup>Deletion of a 28-bp segment (nt 217–244) within the regulatory region. This deletion accompanied 3 nucleotide substitutions at nt 245, 247, and 253**Table 7.** Comparison and distribution of complete JCV DNA sequences detected in family E

Sequence	Nucleotide substitution at:		Rearrangement	No. of clones with the indicated sequence in:	
	nt 3225	nt 3308		Parent	Child
FE-1	G	A	— <sup>a</sup>	2	4
FE-2	G	C	—	3	0
FE-3	A	A	—	0	1


<sup>a</sup>None

region. All of the four sequences were found in the parent, but only FD-1 was found in the child.


Three sequences, FE-1 to -3, were detected in family E (Table 7). These sequences were distinguishable by substitutions at 2 sites, nt 3225 and 3308, within the VP1 and LT genes, respectively. FE-1 and -2 were found in the parent, and FE-1 and -3 were found in the child.

#### *Genotyping JCV DNA sequences detected in the 5 families*

The JCV strains in the world constitute a single serotype [26]. However, they are classified into more than ten subtypes (also designated genotypes) based on nucleotide differences among them [6]. To classify detected JCV DNA sequences into genotypes, we constructed a NJ phylogenetic tree from 17 complete JCV DNA sequences detected in the 5 families together with 64 complete JCV DNA sequences reported previously [2–5, 13, 18, 25, 35]. According to the resultant tree (not shown), (i) the JCV DNA sequences detected in family A belonged to genotype B1-b; (ii) those detected in families B and D belonged to genotype



**Fig. 1.** NJ phylogenetic tree relating complete JCV DNA sequences detected in families B and D. A NJ phylogenetic tree was constructed from 6 complete MY-a/-b sequences detected in families B and D and 13 complete MY sequences detected in unrelated individuals (11 Japanese and 2 Koreans) [4, 18, 35, 44, and Table 2] (the noncoding regulatory region of the JCV genome was excluded from this phylogenetic analysis). The phylogenetic tree was visualized using TREEVIEW. The tree was rooted using a genotype Af2 isolate (ET-3) [35] as the outgroup. The symbols for isolates are shown in Table 2 and described elsewhere [4, 18, 35, 44]. The numbers at nodes in the tree indicate the bootstrap confidence levels (percent) obtained with 1,000 replications (only values  $\geq 50\%$  are shown)



**Fig. 2.** NJ phylogenetic tree relating complete JCV DNA sequences detected in families C and E. A NJ phylogenetic tree was constructed from 11 complete CY sequences detected in families C and E and 11 complete CY sequences detected in unrelated individuals (6 Japanese, 3 Japanese Americans, 2 Mongolians, and 1 Chinese [18, 35, 36]). The phylogenetic tree was visualized using TREEVIEW. The tree was rooted using a genotype Af2 isolate (ET-3) [35] as the outgroup. The symbols for isolates are shown in Table 2 and described elsewhere [18, 35, 36]. The numbers at nodes in the tree indicate the bootstrap confidence levels (percent) obtained with 1,000 replications (only values  $\geq 50\%$  are shown)

MY-b; and (iii) those detected in families C and E belonged to genotype CY. B1-b is mainly prevalent in Central and Western Asia [34], but is rarely detected in Japan [23]. MY-b and CY are both prevalent in Japan [23].

*Phylogenetic comparison of JCV DNA sequences in each family*

As described above, all JCV DNA sequences detected in families B and D belonged to genotype MY. These sequences together with 13 complete MY-a/-b DNA sequences identified in unrelated subjects, including 11 in Japanese and 2 in South Koreans [18, 35, 44, and Table 2], were used to construct a NJ phylogenetic tree (Fig. 1). All JCV DNA sequences detected in families C and E belonged to genotype CY. These sequences together with 11 complete MY DNA sequences previously reported, including 5 in Japanese, 3 in Japanese-Americans, 2 in Mongolians, and 1 in a Chinese [18, 35, 36], were used to construct a NJ phylogenetic tree (Fig. 2). On the resultant trees (Figs. 1 and 2), all sequences detected in each family clustered together at a bootstrap probability of 75–100%. As bootstrap probabilities larger than 70% can be considered to be significant [15], the above result suggests that all JCV DNA sequences in each family were phylogenetically related.

*Alteration in the amino acid sequences of viral proteins*

Nucleotide substitutions detected in JCV DNA sequences and amino acid substitutions predicted by them are shown in reference to prototypical sequences

**Table 8.** Amino acid substitutions caused by nucleotide substitutions in complete JCV DNA clones

JCV DNA sequences	Site of the JCV genome (gene)	Nucleotide substitution <sup>a</sup>	Amino acid substitution <sup>b</sup>
FB-2, -3	nt 1667 (VP1)	A/G	– <sup>c</sup>
FB-3	nt 4109 (LT)	A/G	–
FC-2	nt 3310 (LT)	A/T	–
FC-3, -3a	nt 3065 (LT)	G/A	S/L
FC-4, -4a	nt 3202 (LT)	A/C	–
FC-5	nt 2612 (LT)	G/T	T/N
FC-5	nt 3310 (LT)	A/G	–
FD-2	nt 3308 (LT)	A/T	–
FD-3	nt 2933 (LT)	C/T	–
FE-2	nt 3308 (LT)	A/C	–
FE-3	nt 3225 (LT)	G/A	T/I

<sup>a</sup>[nucleotide in the indicated JCV DNA sequence]/[nucleotide in the hypothetical prototypical JCV DNA sequence] (see text)

<sup>b</sup>[amino acid in the LT encoded by the indicated JCV DNA sequence]/[amino acid in the LT encoded by the hypothetical prototypical JCV DNA sequence] (see text)

<sup>c</sup>None

in Table 8. Eight of the 11 nucleotide substitutions accompanied no amino acid change, but 3 caused amino acid substitutions.

Rearrangements (deletions) in FA-1a and FC-1a were within regions encoding viral proteins, VP2/3 and LT, respectively (Tables 3 and 5). As the deletion in FA-1a caused no frame shift, FA-1a could produce a shorter VP2/3 lacking C-terminal 21 amino acids. On the other hand, the deletion in FC-1a caused a frame shift in the first exon of LT, and therefore FC-1a would have produced a truncated LT containing only 12 N-terminal amino acids.

### Discussion

In this study, we sequenced many complete JCV DNA clones in both parents and children between whom JCV was very probably transmitted. We detected multiple JCV DNA sequences in 4 of the 5 parents and in 3 of the 6 children. It is unlikely that these variations in JCV DNA sequences were introduced during molecular cloning, because of the high fidelity of DNA synthesis in bacterial cells. Phylogenetic analysis suggested that multiple JCV DNA sequences detected in each family are related to each other. As superinfection by a different JCV strain is rather rare [21], it is likely that in each family, one of the detected sequences is the prototypical one from which the others were generated by nucleotide substitution or sequence rearrangement. Although we could not definitely determine which sequence is actually prototypical in each family, it is possible that the sequences at the nodes of family-specific clusters represented the prototypical ones (Figs. 1 and 2).

On the basis of the present data shown in Tables 3, 4, 6, and 7, we could identify JCV DNA sequences that were transmitted from parents to children in families A, B, D, and E. (i) Only a single JCV DNA sequence (FA-1) was detected in the parent of family A, and this sequence was mainly found in two children. Therefore, it was inferred that a JCV strain containing FA-1 was transmitted to 2 children of family A. (ii) Three sequences (FB-1, -2, and -3) were detected in the parent, while only a single sequence (FB-2) was found in the child. Therefore, it was inferred that FB-2 was transmitted from the parent to the child. (iii) Four sequences (FD-1, -1a, -2, and -3) were detected in the parent (Table 6), while only a single sequence (FD-1) was found in the child (Table 6). Therefore, it was inferred that FD-1 was transmitted from the parent to the child. (iv) FE-1 and -2 were detected in the parent of family E, while FE-1 and -3 detected in the child. Therefore, it was inferred that FE-1 was transmitted from the parent to the child.

In family C, however, we could not identify a common sequence in the parent and the child. Six sequences (FC-2, -3, -3a, -4, 4a, and -5) were detected in the parent of family C, while 2 sequences (FC-1 and -1a) were found in the child. According to phylogenetic analysis (Fig. 2), FC-1 was found at the node of the family-C cluster. Although FC-1 was not detected in the urine sample collected from the parent in this study, we may assume that the parent carried FC-1 when he cohabited with his child (this strain may have disappeared in the parent because



of frequent changes in the genome). If this assumption can be accepted, we may infer that FC-1 was transmitted to the child of family C.

To examine the possibility that JCV is transmitted preferentially within the family, Kunitake et al. [24] PCR-amplified the 610-bp IG region from urine specimens collected from all members of 7 families. JCV strains were identified by the nucleotide sequences of the amplified IG regions. From the obtained results, the authors concluded that JCV is transmitted frequently from parents to children. Nevertheless, since JCV strains with identical IG sequences often occur in the same geographical region [8, 14, 23, 27, 33, 34], the detection does not necessarily indicate that a JCV strain was transmitted from the parent to the child. In this study, we detected a completely identical JCV DNA sequence in both the parent and the child belonging to each of the four families. We thus provided support for the proposed mode of JCV transmission, i.e. parent-to-child transmission during cohabitation.

#### Acknowledgement

We are grateful to all urine donors. This study was supported in part by grants from the Ministry of Health, Labor and Welfare, Japan.

#### References

1. Agostini HT, Ryschkewitsch CF, Stoner GL (1996) Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. *J Clin Microbiol* 34: 159–164
2. Agostini HT, Ryschkewitsch CF, Brubaker GR, Shao J, Stoner GL (1997) Five complete genomes of JC virus Type 3 from Africans and African Americans. *Arch Virol* 142: 637–655
3. Agostini HT, Ryschkewitsch CF, Stoner GL (1998) JC virus Type 1 has multiple subtypes: three new complete genomes. *J Gen Virol* 79: 801–805
4. Agostini HT, Shishido-Hara Y, Baumhefner RW, Singer EJ, Ryschkewitsch CF, Stoner GL (1998) JC virus Type 2: definition of genotypes based on DNA sequence analysis of ten complete genomes. *J Gen Virol* 79: 1143–1151
5. Agostini HT, Ryschkewitsch CF, Stoner GL (1998) Complete genome of a JC virus subtype Type 6 from the brain of an African American with progressive multifocal leukoencephalopathy. *J Hum Virol* 1: 267–272
6. Agostini HT, Jobs DV, Stoner GL (2001) Molecular evolution and epidemiology of JC virus. In: Khalili K, Stoner GL (eds) *Human polyomaviruses: molecular and clinical perspectives*. John Wiley & Sons, New York, pp 491–526
7. Ault GS, Stoner GL (1992) Two major types of JC virus defined in progressive multifocal leukoencephalopathy brain by early and late coding region DNA sequences. *J Gen Virol* 73: 2669–2678
8. Chang D, Sugimoto C, Wang M, Tsai RT, Yogo Y (1999) JC virus genotypes in a Taiwan aboriginal tribe (Bunun): implications for its population history. *Arch Virol* 144: 1081–1090
9. Chesters PM, Heritage J, McCance DJ (1983) Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. *J Infect Dis* 147: 676–684

10. Daniel R, Shah K, Madden D, Stagno S (1981) Serological investigation of the possibility of congenital transmission of papovavirus JC. *Infect Immunol* 33: 319–321
11. Dörries K (2001) Latent and persistent polyomavirus infection. In: Khalili K, Stoner GL (eds) *Human polyomaviruses: molecular and clinical perspectives*. John Wiley & Sons, New York, pp 197–235
12. Felsenstein J (1985) Confidence limits on phylogenies: an approach using the bootstrap. *Evolution* 39: 783–791
13. Frisque RJ, Bream GL, Cannella MT (1984) Human polyomavirus JC virus genome. *J Virol* 51: 458–469
14. Guo Z, Zheng SP, Sugimoto C, Wang YL, Zheng HY, Takasaka T, Kitamura T, Guo J, Yogo Y (2001) JC virus genotypes in northwestern China: Implications for its population history. *Anthropol Sci* 109: 203–212
15. Hills DM, Bull JJ (1993) An empirical test of bootstrapping as a method for assessing confidence in phylogenetic analysis. *Syst Biol* 42: 182–192
16. Iida T, Kitamura T, Guo J, Taguchi F, Aso Y, Nagashima K, Yogo Y (1993) Origin of JC polyomavirus variants associated with progressive multifocal leukoencephalopathy. *Proc Natl Acad Sci USA* 90: 5062–5065
17. Kato A, Kitamura T, Sugimoto C, Ogawa Y, Nakazato K, Nagashima K, Hall WW, Kawabe K, Yogo Y (1997) Lack of evidence for the transmission of JC polyomavirus between human populations. *Arch Virol* 142: 875–882
18. Kato A, Sugimoto C, Zheng HY, Kitamura T, Yogo Y (2000) Lack of disease-specific amino acid changes in the viral proteins of JC virus isolates from the brain with progressive multifocal leukoencephalopathy. *Arch Virol* 145: 2173–2182
19. Kimura M (1980) A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. *J Mol Evol* 16: 111–120
20. Kitamura T, Aso Y, Kuniyoshi N, Hara K, Yogo Y (1990) High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. *J Infect Dis* 161: 1128–1133
21. Kitamura T, Kunitake T, Guo J, Tominaga T, Kawabe K, Yogo Y (1994) Transmission of the human polyomavirus JC virus occurs both within the family and outside the family. *J Clin Microbiol* 32: 2359–2363
22. Kitamura T, Sugimoto C, Kato A, Ebihara H, Suzuki M, Taguchi F, Kawabe K, Yogo Y (1997) Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains. *J Clin Microbiol* 35: 1255–1257
23. Kitamura T, Sugimoto C, Ebihara H, Kato A, Guo J, Taguchi F, Tominaga T, Ogawa Y, Ohta N, Kizu N, Imamura K, Funai H, Kurosawa T, Ichikawa S, Suzuki T, Chiba K, Nagashima K, Yasumoto S, Yogo Y (1998) Peopling of Japan as revealing by genotyping of urinary JC virus DNA. *Anthropol Sci* 106: 311–325
24. Kunitake T, Kitamura T, Guo J, Taguchi F, Kawabe K, Yogo Y (1995) Parent-to-child transmission is relatively common in the spread of the human polyomavirus JC virus. *J Clin Microbiol* 33: 1448–1451
25. Loeber G, Dörries K (1988) DNA rearrangements in organ-specific variants of polyomavirus JC strain GS. *J Virol* 62: 1730–1735
26. Major EO (2001) Human polyomavirus. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (eds) *Fields virology*, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Penn, pp 2175–2196
27. Miranda JJ, Sugimoto C, Paraguison R, Takasaka T, Zheng HY, Yogo Y (2003) Genetic diversity of JC virus in the modern Filipino population: Implications for the peopling of the Philippines. *Am J Phys Anthropol* 120: 125–132
28. Nathanson N (1996) Epidemiology. In: Fields BN, Knipe DM, Howley PM (eds) *Fields virology*, vol 1, 3rd edn. Lippincott-Raven, New York, pp 251–271

29. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. *Lancet* i: 1257–1260
30. Padgett BL, Walker DL (1973) Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leucoencephalopathy. *J Infect Dis* 127: 467–470
31. Page RDM (1996) TREEVIEW: An application to display phylogenetic trees on personal computers. *Comp Appl Biosci* 12: 357–358
32. Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Mol Biol Evol* 4: 406–425
33. Saruwatari L, Sugimoto C, Kitamura T, Ohno N, Sakai E, Shresta P, Hoa BK, Phi PTP, An HPH, Tuyet NTA, Honjo T, Kobayashi N, Zheng HY, Takasaka T, Yogo Y (2002) Asian domains of four major genotypes of JC virus, Af2, B1-b, CY and SC. *Arch Virol* 147: 1–10
34. Sugimoto C, Kitamura T, Guo J, Al-Ahdal MN, Shchelkunov SN, Otova B, Ondrejka P, Chollet JY, Safi SEI, Ettayebi M, Grésengué G, Kocagöz T, Chaiyarasamee S, Thant KZ, Thein S, Moe K, Kobayashi N, Taguchi F, Yogo Y (1997) Typing of urinary JC virus DNA offers a novel means of tracing human migrations. *Proc Natl Acad Sci USA* 94: 9191–9196
35. Sugimoto C, Hasegawa M, Kato A, Zheng HY, Ebihara H, Taguchi F, Kitamura T, Yogo Y (2002) Evolution of human polyomavirus JC: implications for the population history of humans. *J Mol Evol* 54: 285–297
36. Suzuki M, Zheng HY, Takasaka T, Sugimoto C, Kitamura T, Beutler E, Yogo Y (2002) Asian genotypes of JC virus in Japanese-Americans suggest familial transmission. *J Virol* 76: 10074–10078
37. Taguchi F, Kajioka J, Miyamura T (1982) Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. *Microbiol Immunol* 26: 1057–1064
38. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 22: 4673–4680
39. Tominaga T, Yogo Y, Kitamura T, Aso Y (1992) Persistence of archetypal JC virus DNA in normal renal tissue derived from tumor-bearing patients. *Virology* 186: 736–741
40. Walker DL, Padgett BL (1983) The epidemiology of human polyomaviruses. *Prog Clin Biol Res* 105: 99–106
41. Yogo Y, Kitamura T, Sugimoto C, Ueki T, Aso Y, Hara K, Taguchi F (1990) Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. *J Virol* 64: 3139–3143
42. Yogo Y, Iida T, Taguchi F, Kitamura T, Aso Y (1991) Typing of human polyomavirus JC virus on the basis of restriction fragment length polymorphisms. *J Clin Microbiol* 29: 2130–2138
43. Yogo Y, Sugimoto C (2001) The archetype concept and regulatory region rearrangement. In: Khalili K, Stoner GL (ed) *Human polyomaviruses: molecular and clinical perspectives*. John Wiley & Sons, New York, pp 127–148
44. Zheng HY, Sugimoto C, Hasegawa M, Kobayashi N, Kanayama A, Rodas A, Mejia M, Nakamichi J, Guo J, Kitamura T, Yogo Y (2003) Phylogenetic Relationships Among JC Virus Strains in Japanese/Koreans and Native Americans Speaking Amerind or Na-Dene. *J Mol Evol* 56: 18–27

Author's address: Dr. Huai-Ying Zheng, Department of Urology, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, 113-8655 Tokyo, Japan; e-mail: teizhy-tyk@umin.ac.jp

# Stability of JC Virus Coding Sequences in a Case of Progressive Multifocal Leukoencephalopathy in Which the Viral Control Region Was Rearranged Markedly

Huai-Ying Zheng, PhD; Yukiharu Yasuda, MD; Shunichi Kato, MD; Tadaichi Kitamura, MD; Yoshiaki Yogo, PhD

• **Context.**—It is generally accepted that JC virus variants in the brains of patients with progressive multifocal leukoencephalopathy are generated from archetypal strains through sequence rearrangement (deletion and duplication, or deletion alone) in the control region. This change is thought to occur during persistence of JC virus in patients.

**Objective.**—The present study was performed to ascertain whether amino acid substitution in the viral proteins is involved in the generation and propagation of JCV variants with rearranged control regions.

**Design.**—Many complete JC DNA clones were established from brain tissues (cerebellum, occipital lobe, and brainstem) autopsied in a case of progressive multifocal leukoencephalopathy in which multiple distinct control sequences were detected. Control and coding sequences

were determined and compared among the JC DNA clones.

**Results.**—Twenty-eight control-region and 20 coding sequences of JC virus were compared. Five rearranged control sequences were detected, but they could be classified into 3 groups that shared common structural features. Viral coding sequences were identical among clones with different control regions and among clones derived from different brain regions.

**Conclusion.**—In the present case, nucleotide substitution in the viral coding regions (and resultant amino acid change in the viral proteins) was involved neither in the genesis of rearranged JC virus variants nor in the proliferation of demyelinated lesions in the brain.

(*Arch Pathol Lab Med.* 2004;128:275–278)

**P**rogressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system that affects individuals with decreased immunocompetence.<sup>1</sup> The causative agent is the human polyomavirus JC virus (JCV), first isolated in 1971 from the brain of a PML patient.<sup>2</sup> Although PML was once a rare disease, it is now a common opportunistic infection in patients with acquired immunodeficiency syndrome.<sup>3</sup>

Most individuals are asymptotically infected with JCV during childhood.<sup>4,5</sup> The infecting JCV reaches the kidney, probably through viremia, and persists there throughout life.<sup>6,7</sup> In adults, the renal JCV replicates and excretes progeny in urine.<sup>8–11</sup> Renal JCV DNA carries the archetype control region (archetype CR),<sup>7</sup> whereas JCV DNA in the brain of PML patients contains various CRs (PML-type CRs) that harbor deletions and duplications, or deletions alone, in reference to the archetype.<sup>12–15</sup>

To explain the correlation between archetype and PML-type JCVs, Yogo and Sugimoto<sup>15</sup> proposed the archetype

concept, which is formulated as follows: (1) JCVs with the archetype CR are circulating in the human population; (2) the archetype CR is highly conserved, in marked contrast to the hypervariable CRs (PML-type CRs) of JCVs in the brain of PML patients; (3) each PML-type CR is produced from the archetype by deletion and duplication, or by deletion alone; (4) the shift of the CR from archetype to PML type occurs during persistence in the host; and (5) PML-type JCVs never return to the human population.

The archetype concept assumes that no amino acid change in the viral proteins is involved in the generation of PML-type JCV. To examine this assumption, we studied a PML case in which multiple, distinct, PML-type JCVs were detected in autopsied brain tissues.<sup>16</sup> We established and sequenced many complete JCV DNA clones. Viral coding sequences were identical among clones with different control regions and among clones derived from different brain regions. We concluded that nucleotide substitution (and resultant amino acid change) was involved neither in the genesis of rearranged JCVs nor in the proliferation of demyelinated lesions in the brain.

## MATERIALS AND METHODS

A detailed case report was published previously.<sup>16</sup> In brief, a 14-year-old boy with Wiskott-Aldrich syndrome suffered from progressive impairment of ocular movement and anarthria 6 months after allogeneic bone marrow transplantation. T2-weighted magnetic resonance imaging showed high-signal areas in the right occipital lobe, cerebellum, and pons. JC viral DNA was detected in the cerebrospinal fluid by nested polymerase chain re-

Accepted for publication November 4, 2003.

From the Department of Urology, The University of Tokyo, Tokyo, Japan (Drs Zheng, Kitamura, and Yogo), and the Department of Pediatrics, Tokai University of School of Medicine, Isehara, Japan (Drs Yasuda and Kato). Dr Yasuda is now with Yasuda Pediatric Clinic, Machida, Japan.

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Yoshiaki Yogo, PhD, Department of Urology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan (e-mail: yogo-iky@umin.ac.jp).